[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0946191T3 - Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme - Google Patents

Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme

Info

Publication number
DK0946191T3
DK0946191T3 DK97947357T DK97947357T DK0946191T3 DK 0946191 T3 DK0946191 T3 DK 0946191T3 DK 97947357 T DK97947357 T DK 97947357T DK 97947357 T DK97947357 T DK 97947357T DK 0946191 T3 DK0946191 T3 DK 0946191T3
Authority
DK
Denmark
Prior art keywords
glp
obesity
analogs
control
administered peripherally
Prior art date
Application number
DK97947357T
Other languages
English (en)
Inventor
Richard D Dimarchi
Suad Efendic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26705788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0946191(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0946191T3 publication Critical patent/DK0946191T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK97947357T 1996-11-05 1997-11-04 Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme DK0946191T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3021396P 1996-11-05 1996-11-05
US08/961,405 US6191102B1 (en) 1996-11-05 1997-10-30 Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
PCT/US1997/020114 WO1998019698A1 (en) 1996-11-05 1997-11-04 Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity

Publications (1)

Publication Number Publication Date
DK0946191T3 true DK0946191T3 (da) 2003-07-14

Family

ID=26705788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97947357T DK0946191T3 (da) 1996-11-05 1997-11-04 Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme

Country Status (19)

Country Link
US (4) US6191102B1 (da)
EP (1) EP0946191B1 (da)
CN (1) CN1268391C (da)
AT (1) ATE234112T1 (da)
AU (1) AU734042B2 (da)
CA (1) CA2271169C (da)
DE (1) DE69719798T2 (da)
DK (1) DK0946191T3 (da)
ES (1) ES2194224T3 (da)
HK (1) HK1024874A1 (da)
HU (1) HUP0003314A3 (da)
IL (1) IL129852A (da)
MY (1) MY129220A (da)
NO (1) NO992557L (da)
NZ (1) NZ335995A (da)
PT (1) PT946191E (da)
UA (1) UA65549C2 (da)
WO (1) WO1998019698A1 (da)
YU (1) YU24199A (da)

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (en) * 1996-11-12 2005-02-23 Novo Nordisk A/S Use of glp-1 peptides
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
ATE381939T1 (de) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
CA2341454A1 (en) * 1998-08-28 2000-03-09 Benjamin Lee Hughes Method for administering insulinotropic peptides
DE69938669D1 (de) 1998-12-07 2008-06-19 Sod Conseils Rech Applic Analoge des glucagon ähnlichen peptides-1 (glp-1)
PL189664B1 (pl) * 1998-12-07 2005-09-30 Sod Conseils Rech Applic Nowy analog GLP-1, kompozycja farmaceutyczna go zawierająca oraz zastosowanie nowego analogu GLP-1
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP2280021B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6569901B2 (en) * 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
EP1276849A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
JP2004513069A (ja) * 2000-05-19 2004-04-30 レストラゲン,インコーポレイテッド ペプチド医薬処方
DZ3388A1 (fr) * 2000-06-16 2001-12-27 Lilly Co Eli Analogues de peptide 1 du type glucagon
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
EP1390061A2 (en) * 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
IL158488A0 (en) * 2001-04-20 2004-05-12 Sinai School Medicine Tir3 a novel taste receptor
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
EP1572885A2 (en) * 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
MXPA04001525A (es) * 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
US7179788B2 (en) * 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
DK1463751T3 (da) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
WO2003057235A2 (en) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP4417113B2 (ja) * 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Glp−1分子の投与方法
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
AU2003225277A1 (en) * 2002-05-02 2003-11-17 Robert Harris Lipid removal from the body
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US7329798B2 (en) * 2002-06-28 2008-02-12 University Of Guelph Harvest-inducible regulatory elements and methods of using same
DE60327771D1 (de) 2002-07-04 2009-07-09 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
US8377869B2 (en) * 2007-10-24 2013-02-19 Mannkind Corporation Method of preventing adverse effects by GLP-1
US8372804B2 (en) * 2007-10-24 2013-02-12 Mannkind Corporation Delivery of active agents
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
RU2376314C2 (ru) 2002-10-02 2009-12-20 Зилэнд Фарма А/С Стабилизированные соединения эксендина-4
PL376473A1 (en) * 2002-10-22 2005-12-27 Waratah Pharmaceuticals, Inc. Treatment of diabetes
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
CA2510199A1 (en) * 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
BRPI0408978B8 (pt) * 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
WO2004094823A2 (en) 2003-04-23 2004-11-04 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7887789B2 (en) 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
EP2368909A1 (en) 2003-06-12 2011-09-28 Eli Lilly and Company GLP-1 analog fusion proteins
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
ATE498404T1 (de) * 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
US7521527B2 (en) 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US7538185B2 (en) 2004-01-08 2009-05-26 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
JP2007519642A (ja) * 2004-01-30 2007-07-19 ワラタ ファーマシューティカルズ, インコーポレイテッド 血糖値を調節するためのglp−1アゴニストとガストリンとの合わせた使用
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA011583B1 (ru) * 2004-03-31 2009-04-28 Сентокор, Инк. Миметические антитела glp-1 человека, композиции, способы и применения
DE602005014969D1 (de) 2004-04-23 2009-07-30 Conjuchem Biotechnologies Inc Verfahren zur aufreinigung von albumin-konjugaten
EP1753730A1 (en) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ ノルディスク アクティーゼルスカブ Glp−1アゴニストを用いた薬剤誘発性肥満の中和
US9089636B2 (en) * 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
ES2543007T3 (es) 2004-08-23 2015-08-13 Mannkind Corporation Micropartículas que comprenden sales de dicetopiperazina para la administración de fármacos
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20090305964A1 (en) * 2005-04-21 2009-12-10 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
CA2608311C (en) 2005-05-13 2012-11-27 Eli Lilly And Company Glp-1 pegylated compounds
US20090233851A1 (en) * 2005-05-27 2009-09-17 Naomi Wakabayashi Insulin Resistance Improver
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
CA2617859A1 (en) 2005-06-30 2007-01-11 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 pharmaceutical compositions
US20070016262A1 (en) 2005-07-13 2007-01-18 Betastim, Ltd. Gi and pancreatic device for treating obesity and diabetes
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
JP5465878B2 (ja) 2005-09-14 2014-04-09 マンカインド コーポレイション 活性薬剤に対する結晶性微粒子表面の親和性を増大させることに基づく薬物処方の方法
US8338368B2 (en) * 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP1973558A4 (en) * 2005-12-13 2009-12-23 Harkness Pharmaceuticals Inc METHODS OF TREATING OBESITY WITH ENTEROSTATIN
US20070149442A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Non-hygroscopic compositions of enterostatin
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Glp−1のポリマ複合体
US20070141145A1 (en) 2005-12-19 2007-06-21 Pharmaln Ltd. Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
MX360812B (es) 2006-02-22 2018-11-16 Mannkind Corp Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo.
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN101460216B (zh) 2006-03-30 2013-06-19 瓦莱里塔斯公司 多筒式流体递送器械
US20100087365A1 (en) * 2006-04-13 2010-04-08 Roland Cherif-Cheikh Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
JP4537495B2 (ja) * 2006-06-23 2010-09-01 エフ.ホフマン−ラ ロシュ アーゲー インスリン分泌性ペプチドの合成
US20080015265A1 (en) * 2006-07-11 2008-01-17 Byron Rubin Methods of treating obesity using satiety factors
KR101193722B1 (ko) * 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US7839952B2 (en) * 2006-12-05 2010-11-23 Provigent Ltd Data rate coordination in protected variable-rate links
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
ES2628063T3 (es) * 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
BRPI0808157A2 (pt) * 2007-02-02 2014-07-01 Redpoint Bio Corp Uso de inibidor de trpm5 para regular insulina e a liberação de glp-1
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
EP3260129A1 (en) * 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
US8980830B2 (en) * 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US20110065633A1 (en) * 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR101629154B1 (ko) 2008-06-13 2016-06-21 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
SG192405A1 (en) * 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
CA2727147A1 (en) 2008-06-17 2009-12-23 Otsuka Chemical Co., Ltd. Glycosylated glp-1 peptide
US8546327B2 (en) * 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2009259883B2 (en) 2008-06-20 2015-02-05 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
CN106317164A (zh) * 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
DK3228320T3 (da) 2008-10-17 2020-03-09 Sanofi Aventis Deutschland Kombination af et insulin og en glp-1-agonist
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5755566B2 (ja) 2008-12-19 2015-07-29 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation アミド系インスリンプロドラッグ
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
EP2427204B1 (en) 2009-05-06 2017-04-05 Janssen Biotech, Inc. Melanocortin receptor binding conjugates
US20100286628A1 (en) * 2009-05-07 2010-11-11 Rainbow Medical Ltd Gastric anchor
US20110066175A1 (en) * 2009-05-07 2011-03-17 Rainbow Medical Ltd. Gastric anchor
US8414559B2 (en) * 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
KR20210027546A (ko) 2009-06-12 2021-03-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
BR112012004335A8 (pt) 2009-09-02 2016-06-21 Merck Sharp & Dohme Composto, composição farmacêutica, e, uso do composto.
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
CN102666580A (zh) 2009-10-30 2012-09-12 大塚化学株式会社 抗原性glp-1类似物的糖链加成物
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2676373T3 (es) * 2009-11-13 2018-07-19 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
JP5892940B2 (ja) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム クラウン化合物及び/又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
EP2359843A1 (en) * 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
IN2012DN06437A (da) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
JP5969461B2 (ja) 2010-04-27 2016-08-17 ジーランド ファーマ アクティーゼルスカブ Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
MX2012013001A (es) * 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
BR112012033225A2 (pt) * 2010-06-24 2017-06-20 Zealand Pharma As análogos do glucagon
WO2012000118A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102643339B (zh) * 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用
BR112013025395B1 (pt) 2011-04-01 2022-02-01 Mannkind Corporation Embalagem de bolha e método de fabricação de uma embalagem de bolhas
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012273365A1 (en) 2011-06-22 2014-01-16 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
WO2013003449A2 (en) * 2011-06-27 2013-01-03 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
JP2014530892A (ja) * 2011-10-28 2014-11-20 ファリス バイオテック ゲーエムベーハー 心臓虚血再灌流障害からの保護のためのポリペプチド
US20140336118A1 (en) * 2011-10-28 2014-11-13 Pharis Biotec Gmbh Polypeptide for the protection against heart ischemia-reperfusion injury
WO2013064669A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
WO2013074910A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
CN104066438B (zh) 2011-12-22 2015-09-23 辉瑞公司 抗糖尿病化合物
US20130172244A1 (en) * 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP2015519309A (ja) 2012-04-16 2015-07-09 カネック ファーマ インコーポレイテッド Ptp−1bインヒビター前駆体としての縮合芳香族ホスホナート誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
KR20150023013A (ko) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 수용체 활성을 나타내는 글루카곤 유사체
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
PL2875043T3 (pl) 2012-07-23 2017-06-30 Zealand Pharma A/S Analogi glukagonu
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
ES2928365T3 (es) 2013-03-15 2022-11-17 Mannkind Corp Composiciones de dicetopiperazina microcristalina, métodos de preparación y uso del mismo
TWI638831B (zh) 2013-05-28 2018-10-21 日商武田藥品工業股份有限公司 胜肽化合物
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
KR102569036B1 (ko) 2013-10-17 2023-08-23 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Gip−glp−1デュアルアゴニスト化合物及び方法
US10028902B2 (en) 2013-11-08 2018-07-24 Baylor Research Institute Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
US9339482B2 (en) 2013-11-22 2016-05-17 Regents Of The University Of Minnesota Methods to treat dysregulated blood glucose disorders
MX2016008977A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de insulina aspart estabilizadas.
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3107560A1 (en) 2014-02-18 2016-12-28 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CA2945240C (en) * 2014-04-11 2021-08-03 Universite Catholique De Louvain Transgenic pig islets and uses thereof for treating diabetes
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MX2017005280A (es) 2014-10-24 2017-08-15 Merck Sharp & Dohme Coagonistas de los receptores de glucagon y de glp-1.
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Gip促效劑化合物及方法
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
CN105854000A (zh) 2015-02-11 2016-08-17 杭州鸿运华宁生物医药工程有限公司 一种药用glp-1r抗体融合蛋白的稳定溶液制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
US11090385B2 (en) 2015-12-21 2021-08-17 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
US9849092B2 (en) 2015-12-21 2017-12-26 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
US10300121B2 (en) 2015-12-21 2019-05-28 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
US11433260B2 (en) 2015-12-21 2022-09-06 Gholam A. Peyman Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
US10136820B2 (en) 2015-12-21 2018-11-27 Gholam A. Peyman Method to visualize very early stage neoplasm or other lesions
US11660229B2 (en) 2015-12-21 2023-05-30 Gholam A. Peyman Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
US10376600B2 (en) 2016-03-03 2019-08-13 Gholam A. Peyman Early disease detection and therapy
US11419543B1 (en) 2016-03-03 2022-08-23 Gholam A. Peyman Early disease detection and therapy
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
CA3024962A1 (en) 2016-05-24 2017-11-30 Takeda Pharmaceutical Company Limited Peptide compound
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
DK3551651T3 (da) 2016-12-09 2024-05-13 Zealand Pharma As Acylerede glp-1/glp-2-dobbeltagonister
CN107266556A (zh) * 2016-12-14 2017-10-20 江苏师范大学 一种非洲爪蟾胰高血糖素样肽‑1(glp‑1)类似物及其应用
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
SG11202000940XA (en) 2017-08-24 2020-02-27 Novo Nordisk As Glp-1 compositions and uses thereof
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CN110237239A (zh) * 2018-03-09 2019-09-17 上海仁会生物制药股份有限公司 用于治疗肥胖和体重管理的glp-1组合物
CN117003874A (zh) 2018-03-20 2023-11-07 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
TW202140062A (zh) 2020-02-18 2021-11-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
US11998765B2 (en) 2020-09-29 2024-06-04 Cancer Rx, LLC Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2024168265A1 (en) 2023-02-10 2024-08-15 Possible Medicines Llc Aav delivery of rna guided recombination system
WO2024168253A1 (en) 2023-02-10 2024-08-15 Possible Medicines Llc Delivery of an rna guided recombination system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5462928A (en) * 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
JPH07505865A (ja) 1992-02-07 1995-06-29 メレルダウファーマスーティカルズ インコーポレイテッド ボンベシンのフェニルアラニン類似体類
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
CA2138161C (en) 1992-06-15 2003-10-21 Glenn C. Andrews Glucagon-like peptide and insulinotropin derivatives
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
GB9502830D0 (en) 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
ES2187756T3 (es) 1996-03-01 2003-06-16 Novo Nordisk As Uso de una composicion farmaceutica que comprende un peptido supresor del apetito.
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ,インコーポレイテッド 胃腸運動を調節するための方法
US5762953A (en) * 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
JP2000517308A (ja) 1996-08-30 2000-12-26 ノボ ノルディスク アクティーゼルスカブ Glp―2誘導体
RU2214419C2 (ru) 1996-08-30 2003-10-20 Ново Нордиск А/С Glp-1 производные
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (en) 1996-11-12 2005-02-23 Novo Nordisk A/S Use of glp-1 peptides

Also Published As

Publication number Publication date
NZ335995A (en) 2001-02-23
YU24199A (sh) 2002-12-10
US6583111B1 (en) 2003-06-24
CA2271169C (en) 2012-09-04
EP0946191B1 (en) 2003-03-12
DE69719798D1 (de) 2003-04-17
ES2194224T3 (es) 2003-11-16
MY129220A (en) 2007-03-30
IL129852A0 (en) 2000-02-29
AU5245798A (en) 1998-05-29
IL129852A (en) 2007-10-31
NO992557L (no) 1999-06-15
CN1242707A (zh) 2000-01-26
CN1268391C (zh) 2006-08-09
US20070173452A1 (en) 2007-07-26
PT946191E (pt) 2003-06-30
EP0946191A1 (en) 1999-10-06
HUP0003314A3 (en) 2001-12-28
CA2271169A1 (en) 1998-05-14
US7211557B2 (en) 2007-05-01
WO1998019698A1 (en) 1998-05-14
HUP0003314A2 (hu) 2001-02-28
AU734042B2 (en) 2001-05-31
US6191102B1 (en) 2001-02-20
DE69719798T2 (de) 2004-02-12
ATE234112T1 (de) 2003-03-15
NO992557D0 (no) 1999-05-27
UA65549C2 (uk) 2004-04-15
US20040018975A1 (en) 2004-01-29
HK1024874A1 (en) 2000-10-27

Similar Documents

Publication Publication Date Title
DK0946191T3 (da) Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
AU3441400A (en) Peptide
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
BG100974A (en) Vaccines against papillomavirus
HK1021824A1 (en) Compositions and methods for treating infections using analogues of indolicidin
GB9806632D0 (en) Peptide factor
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
NO952744L (no) Cytokinbegrensende midler
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
DE69840415D1 (de) Haemasterlin analoge
AU2002216551A1 (en) Activity control during dieting
EP1306092A3 (en) Use of GLP-1 and analogs administered peripherally, in regulation of obesity
WO2003099849A3 (en) Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
GB9604518D0 (en) Novel compounds
BR9902077A (pt) Uso de análogos glp-1 e derivados administrados perifericamente no controle da obsidade
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.
NO952608L (no) Derivatiserte kalsitoniner
WO2003040368A3 (en) Pharmaceutical compositions of marine sponge microciona prolifera